Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013001025
English
Authors' recommendations:
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral-treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild®. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1446
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- HIV Infections
- Carbamates
- Deoxycytidine
- Thiazoles
- Organophosphonates
- Adenine
- Drug Therapy, Combination
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.